KR20170031305A - Iodine radioisotope-labeled azide tracers, preparation method thereof and compositions containing the same as an active ingredient for use Iodine radioisotope-labeling or medical diagnosis - Google Patents
Iodine radioisotope-labeled azide tracers, preparation method thereof and compositions containing the same as an active ingredient for use Iodine radioisotope-labeling or medical diagnosis Download PDFInfo
- Publication number
- KR20170031305A KR20170031305A KR1020150128508A KR20150128508A KR20170031305A KR 20170031305 A KR20170031305 A KR 20170031305A KR 1020150128508 A KR1020150128508 A KR 1020150128508A KR 20150128508 A KR20150128508 A KR 20150128508A KR 20170031305 A KR20170031305 A KR 20170031305A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound represented
- radioactive iodine
- labeled
- compound
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to a radioactive iodine-labeled azide compound, a process for producing the same, and a radioactive iodine label or a medical diagnostic composition containing the same as an active ingredient. The radioactive iodine-labeled azide compound according to the present invention can be used to label radioactive iodine with a rapid reaction rate and a high radiochemical yield through a copper-free click reaction of a biomolecule or nanoparticle containing DBCO (dibenzocyclooctane) Can be used for radioiodine labeling of biomolecules or nanoparticles or for medical diagnosis because it is stable in vivo, is absorbed at a high rate in the liver and kidney and integrated and exhibits a rapid in vitro excretion rate.
Description
The present invention relates to a radioactive iodine-labeled azide-tracer, a process for producing the same, and a radioactive iodine label or a medical diagnostic composition containing the same as an active ingredient.
For decades, radioactive iodine has been used for radioactive labeling of biomolecules for diagnostic and therapeutic purposes. Specifically, 124 I is positron emission tomography (PET), 123 I and 125 I are radioiodine, which is mainly used for single photon emission computed tomography (SPECT), and 131 I It is used in the treatment of diseases such as thyroid cancer.
As described above, since radioactive iodine is widely used medically, various labeling methods have been developed for labeling biomolecules and small molecules of molecules with radioactive iodine. Among them, the electrophilic aromatic substitution reaction shows high efficiency by a method capable of directly labeling the radioactive isotope. However, most of the labeled compounds synthesized through the above labeling method are often unstable in the animal body and often fail to obtain desired image results, and the strong oxidizing agent used for labeling results in reducing the physiological activity of the biomaterial. A method of indirect labeling synthesis of radioactive iodine capable of solving the above problems has been studied and several prosthetic groups have been developed. However, the method of indirectly labeling radioactive iodine, which has been developed so far, has a problem in that a labeled compound is randomly generated due to lack of chemical selectivity for an active group, and an excessive amount of substrate is required for a high yield due to a slow reaction rate have.
Therefore, there is a need to develop a novel radioactive iodine labeling method that can be applied as an imaging diagnostic and therapeutic substance that is stable in living cells and animals and has less side effects from strong oxidants.
Recently, a labeling method using a cyclooctyne compound through a copper-free click reaction has attracted attention as a radioisotope labeling method for nuclear medicine imaging due to its excellent specificity and rapid reaction rate. A method for efficiently synthesizing radioactive isotope 18 F or 64 Cu labeled small molecules and peptides using a copper-free click reaction has been developed.
Accordingly, the inventors of the present invention have found that a radioactive iodine-labeled azide compound reacts with bio-molecules or nanoparticles containing DBCO (dibenzocyclooctane) via a copper-free click reaction to produce radioactive iodine at a high reaction rate and high radiochemical yield Can be labeled, stable in vivo, rapidly absorbed and accumulated in the liver and kidney, exhibit a rapid in vitro excretion rate, and thus can be usefully used for radioiodine labeling and medical diagnosis of biomolecules or nanoparticles And completed the present invention.
It is an object of the present invention to provide an azide compound labeled with radioactive iodine.
Another object of the present invention is to provide a method for preparing the radioactive iodine labeled azide compound.
It is still another object of the present invention to provide a radioactive iodine labeling method of a biomolecule or nanoparticle compound using the radioactive iodine-labeled azide compound.
Another object of the present invention is to provide a biomolecule or nanoparticle compound labeled with radioactive iodine using the radioactive iodine-labeled azide compound.
Yet another object of the present invention is to provide a radioiodine labeling composition comprising the radioactive iodine-labeled azide compound as an active ingredient.
Another object of the present invention is to provide a radioactive iodine labeling composition comprising the radioactive iodine-labeled biomolecules or nanoparticles as an effective ingredient.
It is still another object of the present invention to provide a medical diagnostic composition comprising the radioactive iodine-labeled azide compound as an active ingredient.
In order to achieve the above object,
The present invention provides a compound labeled with radioactive iodine represented by the following formula (1)
[Chemical Formula 1]
In Formula 1,
n is an integer of 2-10; And
X is radioactive iodine.
Also, as shown in the following
Reacting a compound represented by formula (3) with a compound represented by formula (4) to obtain a compound represented by formula (5) (step 1);
Reacting the compound represented by the formula (5) and the compound represented by the formula (6) obtained in the
(Step 3) of reacting a compound represented by the general formula (7) obtained in the above step 2 with a radioiodide metal salt to prepare a compound represented by the general formula (1), to prepare a radioiodine-labeled compound represented by the general formula The method provides:
[Reaction Scheme 1]
In the
A is halogen;
R 1 is a straight or branched C 1- 6 alkyl or C 6- 8 aryl;
n is an integer of 2-10; And
X is radioactive iodine.
Further, the present invention provides a compound represented by the following formula (2)
A biomolecule or nanoparticle compound containing a radioiodine-labeled compound represented by the above formula (1) and DBCO (dibenzocyclooctane) represented by the following formula (9) is subjected to a copper- Wherein the peptide or nanoparticle compound is a compound of formula < RTI ID = 0.0 > (I) < / RTI >
[Reaction Scheme 2]
In the above Reaction Scheme 2,
Z is a biomolecule or nanoparticle;
n is an integer of 2-10; And
X is radioactive iodine.
Further, the present invention provides a compound labeled with radioactive iodine represented by the following formula (2): < EMI ID =
(2)
In Formula 2,
Z is a biomolecule or nanoparticle;
n is an integer of 2-10; And
X is radioactive iodine.
Furthermore, the present invention provides a radioiodine labeling composition comprising the compound represented by Formula 1 as an active ingredient.
The present invention also provides a radioactive iodine labeling composition comprising the compound represented by Formula 2 as an active ingredient.
Furthermore, the present invention provides a composition for medical diagnosis comprising the compound represented by the formula (1) as an active ingredient.
The radioactive iodine-labeled azide compound according to the present invention can be used to label radioactive iodine with a rapid reaction rate and a high radiochemical yield through a copper-free click reaction of a biomolecule or nanoparticle containing DBCO (dibenzocyclooctane) Can be used for radioiodine labeling of biomolecules or nanoparticles or for medical diagnosis because it is stable in vivo, is absorbed at a high rate in the liver and kidney and integrated and exhibits a rapid in vitro excretion rate.
1 is a graph showing data obtained by separating a product using a radiation-TLC according to time in the reaction of step 2 of Example 4. Fig.
Fig. 2 is a graph showing the radioactivity measured in the mouse serum of Example 1 with time. Fig.
FIG. 3 is a graph showing the radioactivity measured in the mouse serum of Example 4 with time. FIG.
FIG. 4 shows the results of intravenous administration of the ICR mouse of Example 1 and measurement of biodistribution in blood or organ over time. FIG.
Hereinafter, the present invention will be described in detail.
The present invention provides a compound labeled with radioactive iodine represented by the following general formula (1).
[Chemical Formula 1]
In
n is an integer of 2-10; And
X is radioactive iodine.
Hereinafter, the compound represented by
In the compound represented by
X is radioactive iodine, preferably X is radioiodine selected from the group consisting of 122 I, 123 I, 124 I, 125 I, 127 I, 131 I and 132 I, more preferably X Lt; / RTI >
The chemical structural feature of the compound represented by
Accordingly, the compound represented by the formula (1) according to the present invention can undergo copper-free click reaction with a compound having a dibenzocyclooctyne group through an azide group in a high yield in a short time, If the compound has a phosphorous group, the radioactive iodine labeling can be facilitated.
Also, as shown in the following
Reacting a compound represented by formula (3) with a compound represented by formula (4) to obtain a compound represented by formula (5) (step 1);
Reacting the compound represented by the formula (5) and the compound represented by the formula (6) obtained in the
(Step 3) of reacting a compound represented by the general formula (7) obtained in the above step 2 with a radioiodide metal salt to prepare a compound represented by the general formula (1), to prepare a radioiodine-labeled compound represented by the general formula ≪ / RTI >
[Reaction Scheme 1]
In the
A is halogen;
R 1 is a straight or branched C 1- 6 alkyl or C 6- 8 aryl;
n is an integer of 2-10; And
X is radioactive iodine.
Hereinafter, a method for preparing the compound represented by
In the process for preparing a compound represented by the
The base may be an organic base such as pyridine, triethylamine, N, N-diisopropylethylamine (DIPEA) or 1,8-diazabicyclo [5.4.0] -7- Inorganic bases such as sodium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, and sodium hydride may be used singly or in an excess amount, and DIPEA is preferably used.
In the process for producing the compound represented by the formula (1) according to the present invention, the step 2 is a step of reacting the halogen group of the compound represented by the formula (5) obtained in the
At this time, as the palladium catalyst is tetrakis (triphenylphosphine) palladium (Pd (Ph 3 P) 4), palladium charcoal (Pd-C), bis (triphenylphosphine) palladium dichloride (PdCl 2 (PPh 3 ) 2 ), tris (dibenzylideneacetone) palladium (Pd 2 (dba) 3 ), [1,1-bis (diphenylphosphino) ferrocene] dichloropalladium (PdCl 2 (dppf)), allylpalladium chloride dimer ([PdCl (allyl)] 2 ), palladium acetate (Pd (OAc) 2), palladium chloride (PdCl 2), and the like, and tetrakis (triphenylphosphine) palladium (Pd (Ph 3 P) 4 ) Is preferably used.
In the method for preparing the compound represented by the formula (1) according to the present invention, the
Here, the radioactive iodide metal salt is a radioactive iodide metal salt. The alkali metal salt includes lithium (Li), sodium (Na), potassium (K), rubidium (Rb) and cesium (Cs) Sodium salt.
Further, the present invention provides a compound represented by the following formula (2)
A biomolecule or nanoparticle compound containing a radioiodine-labeled compound represented by the above formula (1) and DBCO (dibenzocyclooctane) represented by the following formula (9) is subjected to a copper- Wherein the peptide or nanoparticle compound is labeled with a radioactive iodine.
[Reaction Scheme 2]
In the above Reaction Scheme 2,
Z is a biomolecule or nanoparticle;
n is an integer of 2-10; And
X is radioactive iodine.
Hereinafter, the radioactive iodine labeling method represented by Reaction Scheme 2 according to the present invention will be described in detail.
In the radioactive iodine labeling method represented by Reaction Scheme 2 according to the present invention, the radioactive iodine labeling method of the present invention can be used for labeling radioactive iodine-labeled compounds represented by
In the radioactive iodine labeling method represented by Reaction Scheme 2 according to the present invention, the biomolecule is not particularly limited as long as it is a biomolecule containing DBCO (dibenzocyclooctane), but preferably a peptide, an affibody ), An antibody, an oligonucleotide.
Examples of the peptide include RGD peptide, CGNSNPKSC peptide, VHSPNKK peptide, CTTHWGFTLC peptide, SGKGPRQITAL peptide, SGRSA peptide, FSRYLWS peptide and the like, preferably RGD peptide, as a tumor targeting peptide.
In addition, the above-mentioned epitope bodies include, but are not limited to, Aβ peptides, Apolipo protein A1, CD25, CD28, c-Jun, EGFR, Factor VIII, Fibrinogen, Gp120, HER2, IgA, 7 KDa which can be bound to proteins such as IgE, IgM, IL-8, Insulin, RSV G protein, Taq polymerase, TNF-α, Transferrin, Transthyretin, It is a small molecule.
Further, the antibody may be, but not limited to, anti-VEGFR, anti-ERBB2, anti-CD20, anti-CD19, anti-CD22, anti-CD33, anti-CD25, -CEA, Anti-MUC1, and Anti-TAG 72.
The oligonucleotides include, but are not limited to, DNA, RNA, siRNA, and antisense oligonucleotides.
In the radioactive iodine labeling method represented by the reaction formula 2 according to the present invention, the nanoparticles are particularly limited as long as they are nanoparticles containing DBCO (dibenzocyclooctane), but may be metal nanoparticles, synthetic polymer nanoparticles, Polymer nanoparticles, and the like.
The metal nanoparticles may include, but are not limited to, metals such as gold (Au), platinum (Pt), palladium (Pd), silver (Ag), and copper (Cu); Or metal oxides of metals such as cobalt (Co), manganese (Mn), iron (Fe), nickel (Ni), gadolinium (Gd), molybdenum (Mo), zinc (Zn) And preferably gold nanoparticles.
The synthetic polymer nanoparticles include, but are not limited to, poly (ethylene glycol), poly (vinyl alcohol), poly (acrylic acid), polyhydroxy But are not limited to, poly (hydroxyester), poly (ε-caprolactone), poly (orthoester), polymeric anhydride, polyphosphagene, polypropylene fumarate (propylenefumarate), poly (glycolic acid), poly (lactic acid), poly (lactic-co-glycolic acid) (Hydroxybutyrate-co-valerate), poly (urethane), polymethyl methacrylate (poly (hydroxybutyrate-co-valerate) methyl methacrylate)).
Further, the biopolymer nanoparticles may include, but are not limited to, chitin, chitosan, polylysine, hyaluronic acid, alginic acid, dextran, cellulose, .
The nanoparticles are nanoparticles having a size of 1 nm to 1000 nm, preferably 10 nm to 500 nm, and more preferably 50 nm to 200 nm. When the size of the nanoparticles is less than 1 nm, it is difficult to produce the radioactive iodine-labeled nanoparticles according to the present invention. When the size of the nanoparticles is more than 1000 nm, the nanoparticle inherent characteristics may be lost.
According to the labeling method of the present invention, the biomolecule or nanoparticle can be labeled with radioactive iodine by using the compound represented by the formula (1), and the reaction proceeds at a rapid rate within 60 minutes, and at the same time, 80% And exhibits a high radiochemical yield value of 80% or more even in an environment similar to a living body, so that it can be usefully used as a radioactive iodine labeling method.
The present invention also provides a radioactive iodine labeling composition comprising the radioactive iodine-labeled compound represented by
Furthermore, the present invention provides a radioactive iodine labeling composition comprising the radioactive iodine-labeled compound represented by Formula 2 as an active ingredient.
The radioactive iodine is radioiodine selected from the group consisting of 122 I, 123 I, 124 I, 125 I, 127 I, 131 I and 132 I, preferably 125 I.
As a result of measuring the yield of the radiochemical reaction according to the reaction conditions using the compound represented by the formula (1) according to the present invention, the radioactive iodine labeling can be achieved with a high radiochemical yield of 80% to 99% in a short time within 60 minutes, The compound represented by
As a result of evaluating the stability of the compound according to the present invention in vivo, the compounds represented by the formulas (1) and (2) according to the present invention showed high radiochemical purity of 90% or more even after 24 hours or more in mouse serum Therefore, it can be confirmed that the compound according to the present invention is stable in vivo. Accordingly, the compounds represented by formulas (1) and (2) according to the present invention can be effectively used as a composition for radioiodine labeling of a substance in vivo (see Experimental Example 2 and FIGS. 2 and 3).
In addition, the present invention provides a medical diagnostic composition comprising the compound labeled with the radioactive iodine represented by
The radioactive iodine is radioiodine selected from the group consisting of 122 I, 123 I, 124 I, 125 I, 127 I, 131 I and 132 I, preferably 125 I.
In addition, the diagnosis is not limited, but may be performed by a single photon emission computed tomography (SPECT), positron emission tomography (PET), micro-PET, computed tomography (CT), magnetic resonance imaging It is diagnosis by target image.
As a result of labeling DBCO under reaction conditions similar to a living body using the compound represented by the formula (1) according to the present invention, it was confirmed that the reaction proceeded at a high radiochemical yield even in an environment similar to a living body, (See Experimental Example 1 and Table 1).
As a result of measurement of the in vivo distribution of the compound represented by the formula (1) according to the present invention, it was found that the compound was absorbed into the liver and kidney at a rapid rate within 15 minutes and accumulated at a high concentration, and more than 90% Therefore, the compound represented by formula (I) according to the present invention can rapidly diagnose at the time of medical diagnosis and can be prevented from remaining in the body because it is discharged outside the body after diagnosis, (See Experimental Example 3 and Fig. 4).
Hereinafter, examples and experimental examples of the present invention will be described in detail.
However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the present invention is not limited to the following Examples and Experimental Examples.
< Example 1> 125 I < / RTI > labeled N- (2- (2- (2- (2- Ah Mapetoxi ) Ethoxy ) Ethoxy ) Ethyl) -4-iodobenzamide < / RTI >
Step 1: N- (2- (2- (2- (2- Ah Mapetoxi ) Ethoxy ) Ethoxy ) Ethyl) -4- Iodobenzamide Produce
To dry DMF (dimethylformamide) (15 mL) of 2- (2- (2- (2-azidethoxy) ethoxy) ethoxy) ethan- 1- (1240 mg, 5 mmol), HBTU (N, N, N ', N'-tetramethyl-O- (1H- benzotriazol- 1-yl) uronium hexafluorophosphate) mg, 5.26 mmol) and DIPEA (diisopropylethylamine) (1.74 mL) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After the reaction, a 0.2 M aqueous hydrochloric acid solution (50 mL) was added to the reaction solution. The crude product was extracted with ethyl acetate three times, and the organic layers were combined, dried over MgSO 4 (magnesium sulfate) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate = 1: 3) to give N- (2- (2- (2- Amide (2017 mg, 90% yield) as a colorless oil.
1 H NMR (CDCl 3): 7.77 (d, 2H, J = 8.4), 7.52 (d, 2H, J = 8.4), 6.81 (br s, 1H), 3.60-3.66 (m, 14H), 3.35 (t , 2H, J = 5.4).
13 C NMR (CDCl 3 ): 166.94, 137.71, 133.96, 128.85, 98.47, 70.67, 70.65, 70.56, 70.26, 70.08, 69.69, 50.67, 39.94.
HRMS ([M + H] + ) Calcd for C 15 H 22 IN 4 O 4 +: 449.0680; Found 449.0685.
Step 2: N- (2- (2- (2- (2- Ah Mapetoxi ) Ethoxy ) Ethoxy ) Ethyl) -4- ( Tributylstannyl ) ≪ / RTI > benzamide
Ethyl) -4-iodobenzamide (224 mg, 0.5 mmol) obtained in the
1 H NMR (DMSO-d 6 ) 8.42 (t, 1H), 7.72 (d, 2H, J = 8.4), 7.48 (d, 2H, J = 8.4), 3.48-3.54 (m, 12H), 3.32-3.39 (m, 4H), 1.43-1.50 (m, 6H), 1.21-1.29 (m, 6H), 1.02 (t, 6H, J = 8.0), 0.81 (t, 9H, J = 7.3).
13 C NMR (DMSO-d 6 ): 167.02, 146.23, 136.54, 134.64, 126.90, 70.33, 70.30, 70.21, 70.15, 69.76, 69.42, 50.49, 29.11, 27.20, 14.07, 9.71.
HRMS ([M + H] + ) Calcd for C 27 H 49 N 4 O 4 Sn + : 613.2770; Found 613.2781.
step 3: 125 I The labeled N- (2- (2- (2- (2- Ah Mapetoxi ) Ethoxy ) Ethoxy ) Ethyl) -4-iodobenzamide < / RTI >
To a solution of the N- (2- (2- (2- (2-azidethoxy) ethoxy) ethoxy) ethyl) -4- (tributylstannyl) benzamide (1 mg) 200 μL) and chloramine T (40 μL, 2 mg) were added to 1 × PBS. 0.1 M NaOH (100 [mu] L) of [ 125 I] NaI (133 MBq (megabecquerel)) was added to the reaction mixture. The reaction was stirred at room temperature for 15 minutes and quenched with aqueous sodium metabisulfite solution. The crude product was purified by prep HPLC (eluent change: 20% solvent B 0-2 min; 20-80% solvent B 2-22 min; 80-100% solvent B 22-23 min; 100% solvent B 23-28, retention time (retention time: 18.3 minutes) to obtain the target compound (85% radiochemical yield) labeled with 125 I (113 MBq).
Radiochemical purity: 99% (analytical HPLC), specific radioactivity; 40.7 GBq / μmol.
< Example 2> Through copper-free click reaction 125 I-labeled DBCO ( Dibenzocyclooctane ) -Amine < / RTI >
DBCO-amine (2 [mu] L), 125 I-labeled N- (2- (2- (2- (2-azidethoxy) ethoxy) ethoxy) The reaction was carried out by dissolving decabenzamide ([125I] 1, 0.16 MBq, 18 μL) in DMSO (dimethylsulfoxide) or DMSO / mouse plasma (1/1). The total volume of the reaction mixture was fixed at 20 μL and the final concentration of DBCO-amine was changed to 1 mM, 100 μM and 10 μM. The reaction temperature was changed to room temperature or 37 ° C, and the reaction time was changed to 15 minutes or 30 minutes.
Example 2-A
The target compound was obtained by carrying out the same method as in Example 2 except that the amount of DBCO-amine used was 20 mmol, the reaction solvent was DMSO, the reaction temperature was room temperature, and the reaction time was 15 minutes.
Example 2-B
The target compound was obtained by following the same procedure as in Example 2 except that the amount of DBCO-amine used was 20 mmol, the reaction solvent was DMSO, the reaction temperature was room temperature, and the reaction time was 30 minutes.
Example 2-C
The same preparation procedure as in Example 2 was carried out except that the amount of DBCO-amine used was 20 mmol, the reaction solvent was DMSO / mouse serum (1/1), the reaction temperature was 37 ° C, and the reaction time was 30 minutes Compound.
Example 2-D
The same preparation procedure as in Example 2 was carried out except that the amount of DBCO-amine used was 2 mmol, the reaction solvent was DMSO / mouse serum (1/1), the reaction temperature was 37 ° C, and the reaction time was 30 minutes Compound.
Example 2-E
The same preparation procedure as in Example 2 was carried out except that the amount of DBCO-amine used was 0.2 mmol, the reaction solvent was DMSO / mouse serum (1/1), the reaction temperature was 37 ° C, and the reaction time was 30 minutes Compound.
< Example 3> 125 I-labeled DBCO Conjugation (conjugation) cRGD cyclic peptide of arginine - glycine - aspartic ) Of peptide Produce
Step 1: DBCO Conjugated cRGD Of peptide Produce
DMSO (150 μL) and DIPEA (16 μL, 0.09 mmol) in DBCO-NHS ester (9 mg, 0.018 mmol) were dissolved in DMSO (150 μL), and the cRGD peptide (RGDyK, 15 mg, 0.0177 mmol) Peptide solution. The reaction solution was stirred at room temperature for 2 hours. The crude product was purified by prep HPLC (eluent change: 20% solvent B 0-2 min; 20-80% solvent B 2-22 min; 80-100% solvent B 22-23 min; 100% solvent B 23-28 min Time: 10.1 minutes) (11 mg, 61% yield).
MALDI-Tof [M + H] + Calcd for C 49 H 60 N 11 O 11 : 978.4468; Found 978.4368.
step 2: 125 I have Labeled DBCO Conjugation cRGD Of peptide Produce
Ethoxy) Example 1 125 I of the cover obtained from N- (2- (2- (2- ( 2- ethoxy-O mapped) to the compound (1 mM, 2 μL) obtained in Step 1-ethoxy) Ethyl) -4-iodobenzamide ([125I] 1, 1.85 MBq) in DMSO (18 μL). The total volume of the reaction mixture is 20 μL and the volume of 125 I labeled N- (2- (2- (2- (2-azidethoxy) ethoxy) ethoxy) The final concentration is 100 μM. The conjugation reaction was carried out at 37 DEG C for 30 minutes. The radiochemical yield measured by analytical HPLC (eluent change: 40% solvent B 0-2 min; 40-100% solvent B 2-22 min, retention time: 3.96 min) is 67%.
< Example 4> 125 I have Labeled DBCO -PEG- SH Conjugated Gold nanoparticles (gold nanoparticle )
Step 1: DBCO -PEG- SH and Conjugated Fabrication of gold nanoparticles
To the
step 2: 125 I have Labeled DBCO -PEG- SH Conjugation Fabrication of gold nanoparticles
In Example 1 above the 125 I labeling is obtained from N- (2- (2- (2- ( 2- ethoxy-O mapped) to the gold nanoparticle solution (2 μM, 50 μL) obtained in Step 1-ethoxy) Ethoxy) ethyl) -4-iodobenzamide (3.7 MBq) in DMSO (5 μL). The conjugation reaction was carried out at 37 DEG C for 60 minutes. After completion of the reaction, the crude product was purified by centrifugation (15,000 rpm, 20 minutes). After 30 minutes of reaction, after 60 minutes of reaction, and after purification, the product was separated by radiation-TLC (eluent: ethyl acetate), and the yield was calculated by checking the reaction rate. The results are shown in FIG. The final radiochemical yield, measured by radiation-TLC, is 95%.
< Experimental Example 1> Evaluation of radiochemical yield according to reaction conditions
The following experiment was conducted to measure the yield of the radiochemical reaction by varying the amount of DBCO-amine, the type of reaction solvent, the reaction temperature and the reaction time.
The radiochemical yields of the above Examples 2-A to 2-E were determined by analytical HPLC (eluent change: 40% solvent B 0-2 min; 40-100% solvent B 2-22 min, retention time: 5.38 min) . The specific reaction conditions of Examples 2-A to 2-E and the radiochemical yields thereof are shown in Table 1 below.
Table 1 below shows the radiochemical yields according to the amounts of DBCO-amine used, the type of reaction solvent, reaction temperature and reaction time in Example 2.
Amount used (nmol)
(minute)
As shown in Table 1,
Using the embodiment of 125 I are labeled Example 1 according to the invention the reaction in the DBCO (dibenzo cycloocta in) and copper-free according sikineunde cover the 125 I in DBCO through a click reaction, 30 very short reaction time in the When DMSO alone was used, it was confirmed that the 84% mouse plasma mixture solution showed a very high 99% radiochemical yield. In addition, the amount of DBCO was found to be 84% or 99% higher than that of 20 nmol, and it was found that the optimum amount was 20 nmol. The reaction temperature was 37 ° C using DMSO / ℃, it was confirmed that DBCO labeled with 125 I could be obtained at a high rate of radiochemical yield at a short reaction time within 30 minutes.
Thus, the 125 I labeled Example 1 according to the present invention is able to label radioactive iodine with a very high radial chemical yield of 84 to 99% in a DBCO-containing compound within a short reaction time of 30 minutes, Since the reaction proceeds at a high radiochemical yield, 125 I can be effectively labeled in vivo using Example 1 according to the present invention, so that it can be usefully used for radioactive iodine labeling, It can be seen that it is useful.
< Experimental Example 2 > Example Evaluation of stability in mouse serum
In order to evaluate the stability in the mouse serum of the example according to the present invention, the following experiment was conducted.
A partial sample (20 μL, 0.37 MBq) of Example 1 was maintained in normal mouse serum (200 μL) at 37 ° C. for 24 hours. The stability was measured by radiation-TLC, and the results were measured every 0, 1, 5, and 24 hours, and the results are shown graphically in FIG.
A partial sample (20 μL, 0.37 MBq) of Example 4 was maintained in normal mouse serum (200 μL) at 37 ° C. for 24 hours. The stability was measured by radiation-TLC, and the results were measured at 0, 1, 2, 4, 18, and 30 hours, and the results are shown graphically in FIG.
Fig. 2 is a graph showing the radioactivity measured in the mouse serum of Example 1 with time. Fig.
FIG. 3 is a graph showing the radioactivity measured in the mouse serum of Example 4 with time. FIG.
As shown in FIG. 2, Example 1 according to the present invention showed 95% or more of radiochemical purity even after 5 hours in mouse serum and showed high radiochemical purity of 90% or more even after 24 hours , And that it was stable in vivo.
As shown in FIG. 3, Example 4 according to the present invention showed almost no decrease after one hour in mouse serum, maintained a radiochemical purity of 95% or more until after 23 hours, And exhibited chemical purity. Thus, it was confirmed that it was stable in vivo.
Therefore, the compound of the example according to the present invention is stable in the living body and accordingly exhibits a high radiochemical purity over time in vivo, so that it can be used not only for radioiodine labeling but also for medical diagnosis As shown in FIG.
< Experimental Example 3> In vivo Distribution( Biodistribution ) evaluation
In order to evaluate the in vivo distribution of Example 1 according to the present invention, the following experiment was conducted.
Example 1 (1 μCi / 100 μL per mouse) was intravenously administered to 20 male mice ICR. Five mice were sacrificed at 0.25, 1, 2, and 4 hours after anesthesia, The radioactivity was measured with a gamma-counter, and the distribution data were expressed as% ID / g tissue (percentage (%)) / g body injected dose per gram tissue. The results are shown graphically in FIG.
FIG. 4 shows the results of intravenous administration of the ICR mouse of Example 1 and measurement of biodistribution in blood or organ over time. FIG.
As shown in FIG. 4, Example 1 according to the present invention was absorbed into the liver and kidney at a rapid rate within 15 minutes, and accumulated at a high concentration. Within 1 hour, the concentration dropped below 20% As a result, it was found that more than 90% was released into the body within 2 hours.
Therefore, the first embodiment according to the present invention can speed up the diagnosis at the time of medical diagnosis because the integration speed is fast and the time to discharge is fast, and after the diagnosis, the radioactive material remains in the body And can be usefully used for medical diagnosis.
Accordingly, the azide compound represented by formula (1) according to the present invention can be produced by subjecting a biomolecule or nanoparticle containing DBCO (dibenzocyclooctane) to copper-free click reaction at a high reaction rate and high radiochemical yield, Is stable in vivo, is rapidly absorbed and accumulated in the liver and kidney, exhibits a rapid in vitro excretion rate, and thus can be useful for radioiodine labeling or medical diagnosis of biomolecules or nanoparticles .
Claims (15)
[Chemical Formula 1]
(In the formula 1,
n is an integer of 2-10; And
And X is radioactive iodine).
Wherein n is an integer of 3-5.
Wherein X is radioiodine-labeled compound selected from the group consisting of 122 I, 123 I, 124 I, 125 I, 127 I, 131 I and 132 I.
Reacting a compound represented by formula (3) with a compound represented by formula (4) to obtain a compound represented by formula (5) (step 1);
Reacting the compound represented by the formula (5) and the compound represented by the formula (6) obtained in the above step 1 to obtain a compound represented by the formula (7) (step 2); And
(3) reacting a compound represented by the formula (7) obtained in the above step 2 with a radioiodide metal salt to prepare a compound represented by the formula (1) (step 3) : ≪
[Reaction Scheme 1]
(In the above Reaction Scheme 1,
A is halogen;
R 1 is a straight or branched C 1- 6 alkyl or C 6- 8 aryl;
n is an integer of 2-10; And
And X is radioactive iodine).
Wherein the radioactive iodinated metal salt is a radioactive iodinated alkali metal salt.
A biomolecule or nanoparticle compound comprising a radioiodine-labeled compound represented by Chemical Formula 1 and DBCO (dibenzocyclooctane) represented by Chemical Formula 9 is subjected to a copper-free click reaction A method for labeling radioactive iodine of a biomolecule or nanoparticle compound comprising the step of preparing a compound represented by formula (2)
[Reaction Scheme 2]
(In the above Reaction Scheme 2,
Z is a biomolecule or nanoparticle;
n is an integer of 2-10; And
And X is radioactive iodine).
Wherein the biomolecule is any one selected from the group consisting of a peptide, an affibody, an antibody, and an oligonucleotide.
Wherein the nanoparticles are any one selected from the group consisting of metal nanoparticles, synthetic polymer nanoparticles, and biopolymer nanoparticles.
Wherein the metal nanoparticles are any one selected from the group consisting of gold (Au), platinum (Pt), palladium (Pd), silver (Ag), and copper (Cu); Or any one selected from the group consisting of Co, Mn, Fe, Ni, Gd, Mo, Zn and Cr, Wherein the radioactive iodine is a metal oxide.
Wherein the nanoparticles are nanoparticles having a size of 5 nm to 200 nm.
(2)
(In the formula (2)
Z is a biomolecule or nanoparticle;
n is an integer of 2-10; And
And X is radioactive iodine).
The medical diagnosis may be a diagnosis based on a target image of single photon emission tomography (SPECT), positron emission tomography (PET), micro-PET, computed tomography (CT), magnetic resonance imaging (MRI) ≪ / RTI >
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150128508A KR101733973B1 (en) | 2015-09-10 | 2015-09-10 | Iodine radioisotope-labeled azide tracers, preparation method thereof and compositions containing the same as an active ingredient for use Iodine radioisotope-labeling or medical diagnosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150128508A KR101733973B1 (en) | 2015-09-10 | 2015-09-10 | Iodine radioisotope-labeled azide tracers, preparation method thereof and compositions containing the same as an active ingredient for use Iodine radioisotope-labeling or medical diagnosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170031305A true KR20170031305A (en) | 2017-03-21 |
| KR101733973B1 KR101733973B1 (en) | 2017-05-11 |
Family
ID=58502404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150128508A KR101733973B1 (en) | 2015-09-10 | 2015-09-10 | Iodine radioisotope-labeled azide tracers, preparation method thereof and compositions containing the same as an active ingredient for use Iodine radioisotope-labeling or medical diagnosis |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101733973B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102133823B1 (en) * | 2019-06-12 | 2020-07-15 | 한국원자력연구원 | Method for labeling radioisotope, radiolabeled compounds using quinine compound and kit comprising the same for labeling radioisotope |
| CN114181106A (en) * | 2021-12-22 | 2022-03-15 | 苏州市立医院 | Novel small molecular compound for radionuclide iodine labeling and synthetic method thereof |
| US11298431B2 (en) | 2018-07-17 | 2022-04-12 | Korea Atomic Energy Research Institute | Method for labeling radioisotope radiolabeling compound and kit comprising the same for labeling radioisotope |
-
2015
- 2015-09-10 KR KR1020150128508A patent/KR101733973B1/en active IP Right Grant
Non-Patent Citations (4)
| Title |
|---|
| Adam, M. J. et al. Chem. Soc. Rev. 2005, 34, 153. |
| Koo, H. et al. Angew. Chem., Int. Ed. 2012, 51, 11836. |
| Van Nostrand, D. Tyroid 2009, 19, 1381. |
| Yan, R. et al. Am. Chem. Soc. 2013, 135, 703. |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11298431B2 (en) | 2018-07-17 | 2022-04-12 | Korea Atomic Energy Research Institute | Method for labeling radioisotope radiolabeling compound and kit comprising the same for labeling radioisotope |
| KR102133823B1 (en) * | 2019-06-12 | 2020-07-15 | 한국원자력연구원 | Method for labeling radioisotope, radiolabeled compounds using quinine compound and kit comprising the same for labeling radioisotope |
| CN112079898A (en) * | 2019-06-12 | 2020-12-15 | 韩国原子力研究院 | Method for labeling radioactive element using quinone compound, radiolabeled compound, and radioactive element labeling kit |
| CN114181106A (en) * | 2021-12-22 | 2022-03-15 | 苏州市立医院 | Novel small molecular compound for radionuclide iodine labeling and synthetic method thereof |
| CN114181106B (en) * | 2021-12-22 | 2024-03-08 | 苏州市立医院 | Novel small molecular compound for radionuclide iodine labeling and synthesis method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101733973B1 (en) | 2017-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103648533B (en) | For the pre-targeting kit comprising trans cyclo-octene dienophile and diene for being imaged or treating | |
| JP6368745B2 (en) | Pre-target kit, pre-target method and reagent used therefor | |
| Karra et al. | 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent | |
| Morales-Avila et al. | Multimeric system of 99mTc-labeled gold nanoparticles conjugated to c [RGDfK (C)] for molecular imaging of tumor α (v) β (3) expression | |
| Meimetis et al. | Bioorthogonal Fluorophore Linked DFO Technology Enabling Facile Chelator Quantification and Multimodal Imaging of Antibodies | |
| Li et al. | MicroPET imaging of CD13 expression using a 64Cu-labeled dimeric NGR peptide based on sarcophagine cage | |
| JP2021513979A (en) | Chemical conjugates of Evans blue derivatives and their use as radiation therapy and contrast agents to target prostate cancer | |
| CN108699095A (en) | Triggering for marking and targeting for cancer selective can activating metabolism sugar precursor | |
| KR101733973B1 (en) | Iodine radioisotope-labeled azide tracers, preparation method thereof and compositions containing the same as an active ingredient for use Iodine radioisotope-labeling or medical diagnosis | |
| CN105934464B (en) | Dendrimer composition, synthetic method and its application | |
| US11535623B2 (en) | Cryptate compounds | |
| KR101755295B1 (en) | Iodine radioisotope-labeled azide compounds and compositions containing the same as an active ingredient for use Iodine radioisotope-labeling | |
| JP2023554079A (en) | Ligands and their uses | |
| JPH11504002A (en) | Hydroxyalkylphosphine compounds for use as diagnostics and therapeutics and methods for their preparation | |
| Mushtaq et al. | Efficient and Site-Specific 125I-Radioiodination of Bioactive Molecules Using Oxidative Condensation Reaction | |
| JP6848015B2 (en) | Radioactive element labeling method, radioactive labeling compound, and radioactive element labeling kit containing it | |
| KR102230657B1 (en) | Method for labeling radioisotope, radiolabeled compounds and kit comprising the same for labeling radioisotope | |
| EP3011976A1 (en) | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents | |
| US11497821B2 (en) | Method for labeling radioisotope, radiolabeling compounds using quinone compound and kit comprising the same for labeling radioisotope | |
| KR101159068B1 (en) | Novel ligand for preparing molecular imaging probe, molecular imaging probe comprising the ligand, molecular imaging particle comprising the imaging probe, and a process for the preparation thereof, and a pharmaceutical composition comprising the same | |
| EP2366693A1 (en) | Nitroimidazole-amino acid compound type nuclide hypoxia imaging agent and intermediates for preparing them | |
| Auchynnikava et al. | Tetrazine Glycoconjugate for Pretargeted Positron Emission Tomography Imaging of trans-Cyclooctene-Functionalized Molecular Spherical Nucleic Acids | |
| WO2011033033A1 (en) | Labelled biotin conjugates | |
| Wang et al. | Synthesis and biological evaluation of 99mTc (CO) 3 (His–CB) as a tumor imaging agent | |
| Hierlmeier et al. | Radiochemistry and Complex Formation of the Cyclen-Derived Chelator DOTI-Me with Mn2+, Cu2+, Zn2+, Ga3+, In3+, Tb3+, and Lu3+ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |